June 9, 2005 (Press Release) --
Aethlon Medical Announces Hepatitis-C Clinical Trial Site
Aethlon Medical, Inc. (OTCBB: AEMD) www.aethlonmedical.com announced today that Qualtran LLC, a contract research organization (CRO) managing biocompatibility studies and clinical trials for Aethlon in India, has advised the Company that the Apollo Hospital, New Delhi has been retained as a sponsor site for Aethlon's forthcoming Hepatitis-C (HCV) clinical trials in India. "The Apollo Hospital is undisputedly the most prestigious multi-specialty hospital in India and is the largest corporate hospital outside of the United States," stated Mr. Sandeep Malik, President of Qualtran.
Disclaimer: www.investorideas.com/about/disclaimer
Full News: www.investorideas.com/Companies/ViewDocument.asp?ID=3070
Aethlon Medical, Inc. (OTCBB: AEMD) www.aethlonmedical.com announced today that Qualtran LLC, a contract research organization (CRO) managing biocompatibility studies and clinical trials for Aethlon in India, has advised the Company that the Apollo Hospital, New Delhi has been retained as a sponsor site for Aethlon's forthcoming Hepatitis-C (HCV) clinical trials in India. "The Apollo Hospital is undisputedly the most prestigious multi-specialty hospital in India and is the largest corporate hospital outside of the United States," stated Mr. Sandeep Malik, President of Qualtran.
Disclaimer: www.investorideas.com/about/disclaimer
Full News: www.investorideas.com/Companies/ViewDocument.asp?ID=3070

Aethlon Medical, Inc. announced today that Qualtran LLC has advised the Company that Apollo Hospital, New Delhi has been retained as a sponsor site for Aethlon's forthcoming Hepatitis-C clinical trial
Email
Print
SPAM




